Welcome to Molecular Oncology Tumor Boards
The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more.
To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more
Recognize the clinical characteristics and outcomes for patients with FLT3 mutations?
Describe the role of FLT3 inhibitors for the initial treatment of AML?
Understand the role of gene mutations, including CLT3, in the pathologic classification of...
What pathologic features are frequently associated with MSI-H colorectal cancers? What are the NCCN guidelines for Lynch syndrome screening in patients with colorectal cancer or endometrial cancer?
Evaluate the appropriate work up and treatment for HPV-related head and neck cancer
Analyze the interpretation and limitations of p16 staining as a surrogate marker for HPV
Identify the work up and treatment for a head and neck cancer of unknown primary
According to WHO 2016 criteria, what is the most accurate diagnosis and how do we distinguish ET from PMF in era of molecular studies? Does it matter to distinguish early primary myelofibrosis from essential thrombocythemia for management?
How would we...